Top
Endometrial Cancers - Healing Genes
715
post-template-default,single,single-post,postid-715,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Endometrial Cancers

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)


Phase 1

DESCRIPTION:

Emory University researchers are recruiting participants for a study on how well an antibody therapy to target cancer in combination with an FDA-approved antibody (Pembrolizumab) to help the immune system identify tumors can shrink advanced tumors of these solid cancers:

  • Pediatric Solid Tumor
  • Germ Cell Tumor
  • Retinoblastoma
  • Hepatoblastoma
  • Wilms Tumor
  • Rhabdoid Tumor
  • Carcinoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Rhabdomyosarcoma
  • Synovial Sarcoma
  • Clear Cell Sarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Desmoplastic Small Round Cell Tumor
  • Soft Tissue Sarcoma
  • Neuroblastoma

The investigational therapy will require either just the investigatory antibody therapy, or the combination with Pembrolizumab. Follow up will last at least 56 days.


PATIENT MUST:

  • Be 18 years of age or older
  • Have confirmed diagnosis of one of the study’s targeted tumors
  • Not have had prior treatment with an investigational anti-LAG3 therapy

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Antibody infusion and, if applicable, Pembrolizumab infusion.
  3. Follow up over the next 56 days.

LOCATIONS AND CONTACTS:

The study site is at Emory University in Atlanta, GA. Map.

Contacts:

Wayne Saville, MD  |  858-480-3410  |  [email protected]

Phuong Lee  |  858-480-3115  |  [email protected]

 

SPONSOR INFORMATION:

Xencor, Inc.

ICON plc

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03849469

 

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader